Jefferson Capital to Announce First Quarter 2026 Results
Globenewswire· 2026-05-01 04:05
MINNEAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (NASDAQ: JCAP) (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off, insolvency and active consumer accounts, today announced that it will release financial results for the first quarter 2026 after the market close on Thursday, May 14, followed by a webcast at 5:00 pm Eastern Time that day to discuss the Company’s results. The live webcast and archived replay can be accessed in the investor relations ...
Exponent Declares Regular Quarterly Dividend for Q2 2026 and Increases Stock Repurchase Authorization by $50 Million
Globenewswire· 2026-05-01 04:05
MENLO PARK, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.31 per share of common stock to be paid on June 18, 2026 to all common stockholders of record as of June 5, 2026. Exponent has paid, and expects to continue to pay, quarterly dividends each year in March, June, September, and December. Future declarations of quarterly dividends and the establishment of future record and payment dates ar ...
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
Globenewswire· 2026-05-01 04:05
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026PHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the company will deliver an oral presentation at the American Diabet ...
Rivian says US loan for Georgia plant set to be smaller but quicker
Reuters· 2026-05-01 04:04
公司融资与项目进展 - 公司将从美国能源部获得至多45亿美元的贷款 用于在佐治亚州建设工厂 [1] - 此次获批的贷款额度较先前批准的额度减少了约20亿美元 [1] 公司资本支出与工厂建设 - 公司计划利用该笔贷款资金建设其位于佐治亚州的工厂 [1]
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
Globenewswire· 2026-05-01 04:03
SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at three upcoming investor conferences in May and June. 2026 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Tuesday, May 12 at 3:40pm PT / 6:40pm ET 46th Annual William Blair Growth Stock Conference Locati ...
US economic growth bounces back, as AI buildout and consumer spending fuel first quarter
Fox Business· 2026-05-01 04:02
美国一季度GDP增长 - 美国一季度GDP年化增长率为2% 低于市场预期的2.3% [1] - 经济增长从去年第四季度的0.5%和第三季度的4.4%反弹 2025年全年经济增长约2.1% [1][2] 经济增长的主要驱动力 - 一季度GDP增长主要由投资、出口、消费者支出和政府支出推动 [3] - 投资主要集中在设备(特别是计算机及相关设备)以及知识产权产品(如软件)和私人库存 [4] - 消费者支出增长主要由医疗服务(包括医院、护理院和门诊服务)推动 [7] - 政府支出增长源于联邦雇员薪酬在政府停摆结束后增加 [7] - 对国内私人购买者的实际最终销售额(消费者支出与私人固定投资总和)一季度增长2.5% 高于去年第四季度的1.8% [8] 行业投资趋势 - 人工智能建设推动了计算机及相关设备领域的投资 [4] - 软件等知识产权产品投资增加 [4] - 住宅和非住宅建筑投资下降 部分抵消了其他领域的增长 [4] 专家观点 - 专家认为一季度经济核心稳固 由人工智能建设和减税政策推动 这些因素将在年内继续驱动增长 [11] - 能源价格上涨将影响经济表现 目前财政刺激的影响大于高能源价格的拖累 但未来几个月这种平衡将开始转变 [11][12] - 人工智能投资在短期内通过增加资本支出、基础设施建设和能源需求 可能加剧通胀压力 [12] - 当前增长依赖于三大支柱:富裕消费者、人工智能投资和资产价格上涨 这掩盖了基础不均衡的脆弱性 [13]
Rivian downsizes DOE loan to $4.5B of Georgia factory
TechCrunch· 2026-05-01 04:02
Rivian has reworked its loan deal with the Department of Energy and now expects to borrow $4.5 billion to build its new factory in Georgia, down from the original amount of $6.6 billion allocated under the Biden administration. Your next round. Your next hire. Your next breakout opportunity. Find it at TechCrunch Disrupt 2026, where 10,000+ founders, investors, and tech leaders gather for three days of 250+ tactical sessions, powerful introductions, and market-defining innovation. Register now to save up to ...
Monolithic Power Systems Reports First Quarter Results on April 30, 2026
Globenewswire· 2026-05-01 04:01
2026年第一季度财务业绩摘要 - 公司2026年第一季度实现创纪录的季度营收8.042亿美元,环比增长7.1%,同比增长26.1% [2][6] - 按GAAP准则,第一季度毛利率为55.3%,环比微增0.1个百分点;营业利润率为30.0%,环比提升3.4个百分点;净利润为1.932亿美元,环比增长12.6%,每股摊薄收益为3.92美元 [2] - 按非GAAP准则,第一季度毛利率为55.5%,与上季度持平;营业利润率为35.8%,与上季度持平;净利润为2.513亿美元,环比增长6.8%,每股摊薄收益为5.10美元 [3] 按终端市场的营收表现 - **企业数据市场**:第一季度营收2.628亿美元,环比增长12.6%,同比大幅增长97.7%,主要受AI和服务器应用电源管理解决方案销售增长驱动,营收占比升至32.7% [4][9] - **通信市场**:第一季度营收1.115亿美元,环比大幅增长33.1%,同比增长55.5%,主要得益于光模块和交换机电源解决方案销售增长,营收占比升至13.9% [4][8] - **存储与计算市场**:第一季度营收1.744亿美元,环比增长7.6%,主要受存储电源管理解决方案销售增长推动,但同比下降7.5%,营收占比为21.7% [4][10] - **汽车市场**:第一季度营收1.524亿美元,环比微增0.9%,同比增长5.1%,ADAS电源解决方案销售增长部分被USB解决方案销售下降所抵消,营收占比为18.9% [4][11] - **工业市场**:第一季度营收4860万美元,环比下降11.2%,同比增长14.2%,营收占比为6.0% [4][12] - **消费市场**:第一季度营收5450万美元,环比下降17.5%,同比下降4.2%,营收占比为6.8% [4][14] 运营费用与现金流 - 第一季度GAAP运营费用为2.039亿美元,环比下降4.9%;非GAAP运营费用为1.583亿美元,环比上升7.0% [2][3][16] - 股票薪酬及相关费用总额为4850万美元,低于上一季度的6690万美元 [17] - 第一季度末现金、现金等价物及短期投资总额为13.671亿美元,较上季度末增加1.106亿美元 [20][23] - 第一季度运营现金流为2.503亿美元,显著高于上一季度的1.049亿美元 [20][23] 资产负债表关键指标 - 第一季度末应收账款为3.021亿美元,相当于34天的销售未回款天数,较上季度末增加3天 [21][24] - 第一季度末内部库存为6.192亿美元,按本季度营收计算的库存天数为157天,较上季度增加4天;按下一季度预计营收计算的库存天数为140天,较上季度减少3天 [21][22][24] 业务进展与战略 - 公司持续从单一的芯片供应商转型为全面的硅基解决方案提供商,其多元化市场战略展现出韧性 [6] - 在汽车和企业数据(包括服务器)终端市场的项目渠道正在加速,公司赢得了跨客户和跨地区的多个新项目 [13] - 公司已向主要客户送样其首款用于DDR5的高速接口产品 [13] - 公司产能持续增长,目标已从最初的40亿美元提升至近期达到60亿美元 [13] - 公司持续投资新技术,以拓展新的终端市场和应用,并继续扩大和多元化其全球供应链,以把握增长机会并保持供应稳定 [13] 2026年第二季度业绩展望 - 预计第二季度营收在8.90亿美元至9.10亿美元之间 [26] - 预计GAAP毛利率在55.1%至55.7%之间;非GAAP毛利率在55.3%至55.9%之间 [26] - 预计GAAP运营费用在2.191亿美元至2.251亿美元之间;非GAAP运营费用在1.67亿美元至1.71亿美元之间 [26] - 预计股票薪酬及相关费用总额在5380万美元至5580万美元之间 [26] - 预计非GAAP税率为15%,完全摊薄后流通股数在4910万至4950万股之间 [26]
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
Globenewswire· 2026-05-01 04:01
公司财务与业务更新安排 - Ascendis Pharma计划于2026年5月7日美国金融市场开盘前公布2026年第一季度财务业绩并提供业务更新 [1] - 公司将于2026年5月7日美国东部时间上午8:00举办电话会议和网络直播,讨论2026年第一季度财务业绩 [1] - 网络直播链接可在公司官网的“投资者与新闻”版块获取,会议结束后30天内可观看回放 [2] 公司业务与技术 - Ascendis Pharma是一家专注于应用其创新TransCon技术平台的全球生物制药公司 [3] - 公司的核心价值是患者、科学与激情,旨在通过TransCon技术开发具有同类最佳潜力的新疗法,以解决未满足的医疗需求 [3] - 公司总部位于丹麦哥本哈根,并在欧洲和美国设有其他设施 [3] 公司商标与联系方式 - Ascendis、Ascendis Pharma、Ascendis Pharma标志、公司标志和TransCon均为Ascendis Pharma集团拥有的商标 [5] - 投资者联系人:Chad Fugere,电话 +1 (650) 519-7494 [6] - 媒体联系人:Melinda Baker,电话 +1 (650) 709-8875 [6]
Atlanticus to Host First Quarter 2026 Earnings Call and Webcast on May 7, 2026 at 5:00 p.m. ET
Globenewswire· 2026-05-01 04:01
ATLANTA, April 30, 2026 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced that it will host a conference call and live webcast to discuss its first quarter financial results and operating performance on Thursday, May 7, 2026 at 5:00 p.m. Eastern Time. The live web ...